Nanotechnology Now - Press Release: Entest BioMedical, Inc. in Discussions to Acquire Nanotechnology Delivery System for Cancer Therapy

Home > Press > Entest BioMedical, Inc. in Discussions to Acquire Nanotechnology Delivery System for Cancer Therapy

Abstract:
Entest BioMedical Inc. (OTC PINK: ENTB) announced today that the Company is currently in discussions to acquire a nanotechnology for the delivery of cancer therapeutics in both animals and humans.

Entest BioMedical, Inc. in Discussions to Acquire Nanotechnology Delivery System for Cancer Therapy

San Diego, CA | Posted on June 3rd, 2015

This technology would potentially allow more potent therapeutics to be administered to patients than is currently possible. The reason this is possible is due to the fact that the nanoparticles sequester the drug and allow it to travel throughout the body with minimal toxicity, only releasing the drug directly to the tumor.

A Company spokesman stated: "We are enthusiastic about this potential acquisition. Although Entest has historically focused on veterinary biotechnology, we believe that the acquisition of this nanotechnology would enable us to pursue partnering opportunities in the human market as well as the veterinary market."

####

About Entest BioMedical Inc.
Entest BioMedical Inc. (OTC PINK: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The Company is also pursuing cancer therapeutics for veterinary application.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

For more information, please click here

Contacts:
Entest BioMedical Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404 Phone
619-330-2328 Fax
www.entb.net

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: